SG11202001654TA - Antibodies targeting pdl1 and methods of use thereof - Google Patents
Antibodies targeting pdl1 and methods of use thereofInfo
- Publication number
- SG11202001654TA SG11202001654TA SG11202001654TA SG11202001654TA SG11202001654TA SG 11202001654T A SG11202001654T A SG 11202001654TA SG 11202001654T A SG11202001654T A SG 11202001654TA SG 11202001654T A SG11202001654T A SG 11202001654TA SG 11202001654T A SG11202001654T A SG 11202001654TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- antibodies targeting
- targeting pdl1
- pdl1
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17195781.4A EP3470429A1 (en) | 2017-10-10 | 2017-10-10 | Antibodies targeting pdl1 and methods of use thereof |
EP18167094 | 2018-04-12 | ||
EP18180816 | 2018-06-29 | ||
PCT/EP2018/077511 WO2019072869A1 (en) | 2017-10-10 | 2018-10-09 | Antibodies targeting pdl1 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001654TA true SG11202001654TA (en) | 2020-03-30 |
Family
ID=63834022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001654TA SG11202001654TA (en) | 2017-10-10 | 2018-10-09 | Antibodies targeting pdl1 and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200283528A1 (en) |
EP (1) | EP3694879A1 (en) |
JP (2) | JP2021501569A (en) |
KR (1) | KR20200063147A (en) |
CN (1) | CN111225926A (en) |
AU (1) | AU2018348430A1 (en) |
CA (1) | CA3074802A1 (en) |
IL (1) | IL273578A (en) |
MA (1) | MA50353A (en) |
SG (1) | SG11202001654TA (en) |
WO (1) | WO2019072869A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020006999A2 (en) * | 2017-10-10 | 2020-10-06 | Numab Therapeutics AG | multispecific antibody, pharmaceutical composition and production method |
EA202190495A1 (en) * | 2019-04-26 | 2022-02-03 | Ай-Маб Биофарма Юэс Лимитед | ANTIBODIES AGAINST HUMAN PD-L1 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
JP4157160B2 (en) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | Methods for the preparation of modified antibody variable regions |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
JP4511943B2 (en) * | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
KR101934071B1 (en) * | 2009-11-24 | 2019-01-02 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
WO2014180577A1 (en) * | 2013-05-10 | 2014-11-13 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
TWI680138B (en) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
EP3307776A1 (en) | 2015-06-15 | 2018-04-18 | Numab Innovation AG | Hetero-dimeric multi-specific antibody format |
CN106939047B (en) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | PD-L1 antibody and preparation method thereof |
WO2017123650A2 (en) * | 2016-01-11 | 2017-07-20 | Inhibrx Lp | Multivalent and multispecific 41bb-binding fusion proteins |
-
2018
- 2018-10-09 AU AU2018348430A patent/AU2018348430A1/en active Pending
- 2018-10-09 WO PCT/EP2018/077511 patent/WO2019072869A1/en unknown
- 2018-10-09 CN CN201880065379.0A patent/CN111225926A/en active Pending
- 2018-10-09 JP JP2020520150A patent/JP2021501569A/en active Pending
- 2018-10-09 US US16/753,876 patent/US20200283528A1/en active Pending
- 2018-10-09 KR KR1020207008775A patent/KR20200063147A/en not_active Application Discontinuation
- 2018-10-09 EP EP18785592.9A patent/EP3694879A1/en active Pending
- 2018-10-09 MA MA050353A patent/MA50353A/en unknown
- 2018-10-09 CA CA3074802A patent/CA3074802A1/en active Pending
- 2018-10-09 SG SG11202001654TA patent/SG11202001654TA/en unknown
-
2020
- 2020-03-24 IL IL273578A patent/IL273578A/en unknown
-
2023
- 2023-08-10 JP JP2023131574A patent/JP2023166403A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA50353A (en) | 2020-08-19 |
CA3074802A1 (en) | 2019-04-18 |
US20200283528A1 (en) | 2020-09-10 |
JP2021501569A (en) | 2021-01-21 |
AU2018348430A1 (en) | 2020-03-12 |
WO2019072869A1 (en) | 2019-04-18 |
JP2023166403A (en) | 2023-11-21 |
KR20200063147A (en) | 2020-06-04 |
CN111225926A (en) | 2020-06-02 |
IL273578A (en) | 2020-05-31 |
EP3694879A1 (en) | 2020-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265800A (en) | Anti-lag-3 antibodies and methods of use thereof | |
PT3618863T (en) | Anti-tigit antibodies and methods of use thereof | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
HK1249445A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
IL259495A (en) | Antibodies and methods of use thereof | |
HK1252698A1 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
HK1252696A1 (en) | Anti-siglec-7 antibodies and methods of use thereof | |
SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL270793A (en) | Anti-htra1 antibodies and methods of use thereof | |
IL265957A (en) | Anti-c1s antibodies and methods of use thereof | |
IL273841A (en) | Antibodies targeting cd137 and methods of use thereof | |
IL268568A (en) | Trailshort antibody and methods of use | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
IL273578A (en) | Antibodies targeting pdl1 and methods of use thereof | |
ZA202002144B (en) | Antibodies and methods of use |